Asthma Drug Fluticasone Fails as Potential COVID-19 Treatment
THURSDAY, July 14, 2022 (HealthDay News) -- The asthma drug fluticasone furoate is yet another medication that does not work for mild-to-moderate COVID-19, a new study finds. The study was published online July 13 in medRxiv, which publishes studies before they have been peer-reviewed.
"There was no evidence of improvement in time to recovery or reduction in hospitalizations in participants who took fluticasone furoate versus those who took a placebo," lead researcher Adrian Hernandez, M.D., executive director of the Duke Clinical Research Institute in Durham, North Carolina, said in a Duke news release.
The finding comes from a nationwide study of nearly 5,000 participants that continues to evaluate the potential benefit of existing drugs to treat mild-to-moderate COVID-19. Fluticasone furoate is one of three U.S. Food and Drug Administration-approved repurposed medications currently being tested against COVID-19.
Fluticasone furoate is an inhaled corticosteroid used to treat asthma, but it is not approved to treat COVID-19. This drug was tested because corticosteroids had seemed potentially beneficial for treating COVID-19 among nonhospitalized patients. Based on the findings, fluticasone furoate should not be used to treat COVID-19, the researchers stressed.
Abstract/Full Text (subscription or payment may be required)
Related Posts
¿Verrugas? ¿Lunares? Los productos que prometen tratarlos pueden de verdad hacer daño
LUNES, 20 de junio de 2022 (HealthDay News) -- Quizá parezca tentador quitarse...
Más evidencias de que la infección con la COVID conlleva riesgos cardiacos a largo plazo
JUEVES, 10 de febrero de 2022 (HealthDay News) -- Una investigación reciente...
Nerve-Cooling Implant Could Ease Pain Without Opioids
FRIDAY, July 1, 2022 (HealthDay News) -- Hinting at a future alternative to...
Los CDC investigan un brote de Salmonella vinculado con harina
LUNES, 3 de abril de 2023 (HealthDay News) -- Las autoridades de salud de EE....